Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 125-132 , March 2008

Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center

  • Elizabeth M. Grainger, Ph.D.

      Affiliations

    • Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, OH 43210, USA
    • ,
  • H. Sunny Kim, Ph.D.

      Affiliations

    • School of Public Health, Center for Biostatistics, Ohio State University, Columbus, OH 43210, USA
    • ,
  • J. Paul Monk, M.D.

      Affiliations

    • Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, OH 43210, USA
    • ,
  • Stanley A. Lemeshow, Ph.D.

      Affiliations

    • School of Public Health, Center for Biostatistics, Ohio State University, Columbus, OH 43210, USA
    • ,
  • Michael Gong, M.D.

      Affiliations

    • Division of Urology, Department of Surgery, Ohio State University, Columbus, OH 43210, USA
    • ,
  • Robert R. Bahnson, M.D.

      Affiliations

    • Division of Urology, Department of Surgery, Ohio State University, Columbus, OH 43210, USA
    • ,
  • Steven K. Clinton, M.D.

      Affiliations

    • Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, OH 43210, USA
    • Division of Urology, Department of Surgery, Ohio State University, Columbus, OH 43210, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-614-293-8396; fax: +1-614-293-7525.

Received 9 August 2006 ,Revised 12 January 2007 ,Accepted 12 January 2007.

References 

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  2. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: An autopsy study of 249 cases. In Vivo. 1994;8:439–443
  3. Thompson IM, Tangen CM, Goodman P. The Prostate Cancer Prevention Trial: Design, status, and promise. World J Urol. 2003;21:28–30
  4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  5. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996;276:1957–1963
  6. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol. 2004;171:907–910
  7. Heinonen OP, Albanes D. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029–1035
  8. John EM, Dreon DM, Koo J, et al. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol. 2004;89–90:549–552
  9. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res. 2001;61:7071–7078
  10. McCullough ML, Giovannucci EL. Diet and cancer prevention. Oncogene. 2004;23:6349–6364
  11. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol. 2004;171:S59–S62
  12. Platz EA, Fleitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2007;98:1819–1825
  13. Sandler RS, Halabi S, Kaplan EB, et al. Use of vitamins, minerals and nutritional supplements by participants in a chemoprevention trial. Cancer. 2001;91:1040–1045
  14. Fitzpatrick AL, Daling JR, Furberg CD, et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11:534–542
  15. de la Taille A, Buttyan R, Hayek O, et al. Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol. 2000;164:1229–1234
  16. Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001;58:960–964
  17. Pytel YA, Vinarov A, Lopatkin N, et al. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther. 2002;19:297–306
  18. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595–3603
  19. Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology. 2001;15:1272–1278
  20. Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer. 2000;88:615–619
  21. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: Data from the National Health and Nutrition Examination Survey, 1999–2000. Am J Epidemiol. 2004;160:339–349
  22. Hoggatt KJ, Bernstein L, Reynolds P, et al. Correlates of vitamin supplement use in the United States: Data from the California Teachers Study cohort. Cancer Causes Control. 2002;13:735–740
  23. Dwyer J, Picciano MF, Raiten DJ. Collection of food and dietary supplement intake data: What We Eat in America- NHANES. J Nutr. 2003;133:590S–600S
  24. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States (The Slone Survey). JAMA. 2002;287:337–344
  25. Neuhouser ML, Kristal AR, Patterson RE, et al. Dietary supplement use in the prostate cancer prevention trial: Implications for prevention trials. Nutr Cancer. 2001;39:12–18
  26. White E, Patterson RE, Kristal AR, et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol. 2004;159:83–93
  27. Messina M, Gardner C, Barnes S. Gaining insight into the health effects of soy but a long way still to go: Commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr. 2002;132:547S–551S
  28. Zhou JR, Gugger ET, Tanaka T, et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999;129:1628–1635
  29. Zhou JR, Mukherjee P, Gugger ET, et al. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res. 1998;58:5231–5238
  30. Erdman JW. AHA Science Advisory: Soy protein and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation. 2000;102:2555–2559
  31. Lampe JW, Gustafson DR, Hutchins AM, et al. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev. 1999;8:699–707
  32. Boileau TW, Liao Z, Kim S, et al. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst. 2003;95:1578–1586
  33. Clinton SK. Tomatoes or lycopene: A role in prostate carcinogenesis?. J Nutr. 2005;135:2057S–2059S
  34. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995;87:1767–1776

☆ This work was supported by the Ohio State University Comprehensive Cancer Center Grant P30 CA16058 and the Prostate Cancer Prevention Fund of the James Cancer Hospital and Solove Research Institute.

PII: S1078-1439(07)00013-0

doi: 10.1016/j.urolonc.2007.01.016

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 125-132 , March 2008

Article Tools

* Image Usage & Resolution